4-(3-氟苯基）-哌啶盐酸盐 | 104774-94-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(3-氟苯基）-哌啶盐酸盐
• 中文别名: 4-(3-氟苯基)-哌啶盐酸盐；4-(3-氟苯基)哌啶盐酸盐
• 英文名称: 4-(3-fluorophenyl)piperidine hydrochloride
• 英文别名: 4-(3-fluorophenyl)piperidine;hydrochloride
• CAS: 104774-94-9
• 化学式: C₁₁H₁₄FN*ClH
• mdl: MFCD02178901
• 分子量: 215.698
• InChiKey: KZWKZINPPPZZCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.22
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.454
• 拓扑面积：
  12
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  1-甲基-2-甲酰苯并咪唑 、 4-(3-氟苯基）-哌啶盐酸盐 在 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 2-((4-(3-氟苯基)哌啶-1-基)甲基)-1-甲基-1H-苯并[d]咪唑
  参考文献：
  名称：

  1-[(1-Methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 Positive Allosteric Modulators for the Treatment of Psychosis

  摘要：

  A novel series of mGluR2 positive allosteric modulators (PAMs), 1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines, is herein disclosed. Structure-activity relationship studies led to potent, selective mGluR2 PAMs with excellent pharmacokinetic profiles. A representative lead compound (+)-17e demonstrated dose-dependent inhibition of methamphetamine-induced hyperactivity and mescaline-induced scratching in mice, providing support for potential efficacy in treating psychosis.

  DOI：

  10.1021/jm101414h

文献信息

• SULTAM DERIVATIVES
  申请人：Anderson Kevin W.

  公开号：US20110124686A1

  公开（公告）日：2011-05-26

  The present invention relates to compounds according to formula 1, which exhibit cytotoxic activity. The compounds may be used in the treatment of cancer.

  本发明涉及符合式1的化合物，具有细胞毒活性。这些化合物可用于治疗癌症。
• XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS
  申请人：Southern Research Institute

  公开号：US20200399271A1

  公开（公告）日：2020-12-24

  The present disclosure is concerned with xanthine analogs, methods of making xanthine analogs, and methods of treating West Nile virus using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及黄嘌呤类似物，制备黄嘌呤类似物的方法，以及使用这些类似物治疗西尼罗河病毒的方法。本摘要旨在作为特定领域搜索的扫描工具，不打算限制本发明。
• [EN] ARYL PIPERIDINES AS MONOACYLGLYCEROL LIPASE MODULATORS<br/>[FR] ARYLPIPÉRIDINES EN TANT QUE MODULATEURS DE LA MONOACYLGLYCÉROL LIPASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021191384A1

  公开（公告）日：2021-09-30

  Aryl piperidine compounds of Formula (I), and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, pharmaceutical compositions containing them, and methods of using them including methods for treating disease states, disorders, and conditions associated with MGL modulation, such as those associated with pain, psychiatric disorders, neurological disorders (including, but not limited to major depressive disorder, treatment resistant depression, anxious depression, autism spectrum disorders, Asperger syndrome, bipolar disorder), cancers and eye conditions: wherein X, R2a, R2b, R3, R4, R5a and R5b are as defined herein.

  化学式（I）的芳基哌啶化合物，以及其药用可接受的盐、同位素、N-氧化物、溶剂合物和立体异构体，含有它们的药物组合物，以及使用它们的方法，包括用于治疗与MGL调节相关的疾病状态、障碍和情况的方法，例如与疼痛、精神障碍、神经系统障碍（包括但不限于重性抑郁障碍、治疗抵抗性抑郁症、焦虑性抑郁症、自闭症谱系障碍、阿斯伯格综合征、躁郁症）、癌症和眼部疾病相关的情况：其中X、R2a、R2b、R3、R4、R5a和R5b的定义如本文所述。
• Modulators of CB1 Receptors
  申请人：Cooper Martin

  公开号：US20100144701A1

  公开（公告）日：2010-06-10

  Compounds of formula (I) suppress the normal signalling activity CB1 receptors, and are thus useful in the treatment of diseases or conditions which are mediated by CB1 receptor signalling activity, such as treatment of obesity and overweight, prevention of weigh gain, treatment of diseases and conditions directly or indirectly associated with obesity and overweight: wherein A 1 is hydrogen, —COOH,or tetrazolyl; p and q are independently 0 or 1; A3 is phenyl or cycloalkyl, either of which is optionally substituted with R 4 and/or R 5 ; R 4 and R 5 are independently —R 9 , —CN, —F, —Cl, —Br, —OR 9 , —NR 7 R 8 , —NR 7 COR 6 , —NR 7 SO 2 R 6 , —COR 6 , —SR 9 , —SOR 9 , or —SO 2 R 6 ; R 6 is C 1 -C 4 alkyl, cycloalkyl, —CF 3 or —NR 7 R 8 ; R 7 and R 8 are independently hydrogen, C 1 -C 4 alkyl or cycloalkyl; R 9 is hydrogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 alkoxy(C 1 -C 4 alkyl)-, cycloalkyl, or fully or partially fluorinated C 1 -C 4 alkyl; R 1 (i) a bond; (ii) a divalent radical of formula —(CH 2 ) a B 1 (CH 2 ) b wherein a and b are independently O, 1, 2 or 3 provided that a+b is 1, 2 or 3, and B 1 is —CO—, —O—, —S—, —SO—, —SO 2 —, —CH 2 —, —CHCH 3 —, —CHOH— or —NR 7 —; or (iii) a divalent radical selected from —C(R 10 )(R 11 )—*, —C(R 10 )(R 11 )—O—*, —C(R 10 )(R 11 )CH 2 —*, —C(R 10 )(R 11 )CH 2 —O—*, —CH 2 C(R 10 )(R 11 )—*, —CH 2 C(R 10 )(R 11 )—O—*, —CH 2 —O—C(R 10 )(R 11 )—* and —C(R 10 )(R 11 )—O—CH 2 —*, wherein the bond indicated by an asterisk is attached to the pyrazole ring; Z is as defined in the specification; R 10 is hydrogen and R 11 is (C 1 -C 3 )alkyl or —OH; or R 10 and R 11 are both (C 1 -C 3 )alkyl; or R 10 and R 11 taken together with the carbon atom to which they are attached form a (C 3 -C 5 )cycloalkyl ring.

  式(I)的化合物抑制CB1受体的正常信号活动，因此可用于治疗由CB1受体信号活动介导的疾病或症状，例如肥胖和超重的治疗，预防体重增加，直接或间接与肥胖和超重相关的疾病和症状的治疗：其中A1是氢，-COOH或四唑基；p和q独立地为0或1；A3是苯基或环烷基，其中任一可选地用R4和/或R5取代；R4和R5独立地为-R9，-CN，-F，-Cl，-Br，-OR9，-NR7R8，-NR7COR6，-NR7SO2R6，-COR6，-SR9，-SOR9或-SO2R6；R6是C1-C4烷基，环烷基，-CF3或-NR7R8；R7和R8独立地为氢，C1-C4烷基或环烷基；R9为氢，C1-C4烷基，C1-C4烷氧基，C1-C4烷氧基（C1-C4烷基）-，环烷基或完全或部分氟化的C1-C4烷基；R1(i)为键；（ii）为式-（CH2）aB1（ ）b的二价基团，其中a和b独立地为O，1，2或3，前提是a+b为1，2或3，B1为-CO-，-O-，-S-，-SO-，-SO2-，- -，-CHCH3-，-CHOH-或-NR7-；或（iii）为从-C（R10）（R11）- *，-C（R10）（R11）-O- *，-C（R10）（R11） - *，-C（R10）（R11） - O- *，- C（R10）（R11）- *，- C（R10）（R11）-O- *，- -O-C（R10）（R11）- *和-C（R10）（R11）-O- - *中选择的二价基团，其中由星号表示的键连接到吡唑环；Z如规范中所定义；R10为氢，R11为（C1-C3）烷基或-OH；或R10和R11均为（C1-C3）烷基；或R10和R11与它们连接的碳原子一起形成（C3-C5）环烷基环。
• Optimizing and characterizing 4-methyl substituted pyrazol-3-carboxamides leading to the peripheral cannabinoid 1 receptor inverse agonist TM38837
  作者：Thomas Högberg、Jean-Marie Receveur、Anthony Murray、Jean-Michel Linget、Pia K. Nørregaard、Paul B. Little、Martin Cooper

  DOI：10.1016/j.bmcl.2023.129572

  日期：2024.1

  with respect to lipophilicity, solubility, CB1 potency, metabolism, distribution to brain and liver, effect on weight loss in diet-induced mice models. A few carboxylic acids and tetrazoles were selected as especially promising with the tetrazole TM38837 subsequently demonstrating impressive efficacy in various animal models of obesity, producing considerable weight loss and improvements on plasma markers

  由相应的 4-氰基甲基吡唑制备了几个系列的用 4-甲基酰胺、4-甲基羧酸和 4-甲基四唑功能化的不同吡唑-3-甲酰胺，并作为大麻素受体 1 (CB1) 拮抗剂和反向激动剂进行了研究，目的是制备化合物与利莫那班相比，CNS（中枢神经系统）介导的副作用更少。对这些化合物的亲脂性、溶解度、CB1 效力、代谢、大脑和肝脏分布以及对饮食诱导小鼠模型体重减轻的影响进行了评估和优化。一些羧酸和四唑被选择为特别有前途的四唑TM38837，随后在各种肥胖动物模型中表现出令人印象深刻的功效，产生显着的体重减轻并改善炎症和葡萄糖稳态的血浆标志物，其剂量显然产生可忽略不计的脑暴露。 TM38837 成为第一个进入临床试验的外周限制性 CB1 拮抗剂或反向激动剂，支持其缺乏 CNS 作用，现在认为非 CNS 介导的功效与高肝脏暴露有关。这为探索非酒精性脂肪肝（NAFLD）和脂肪性肝炎（NASH）等其他适应症提供了机